Clinical trial
Ecteinascidin 743 in Treating Children With Refractory Solid Tumors
NCT00006463 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00006463 |
|---|---|
| Title | Ecteinascidin 743 in Treating Children With Refractory Solid Tumors |
| Official title | Phase I Study of ET-743 in Pediatric Refractory Solid Tumors |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Childhood Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | ECTEINASCIDIN 743 |
| Enrollment | 13 |
| Start date | Oct 1, 2000 |
| Primary completion | Jan 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | Apr 26, 2004 |
| Last update posted | Feb 21, 2014 |
| Countries | Australia, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: